{"id":"NCT00453063","sponsor":"Organon and Co","briefTitle":"Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg Once Daily (QD) in the Treatment of Seasonal Allergic Rhinitis (Study P05067)(COMPLETED)","officialTitle":"Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Treatment of Seasonal Allergic Rhinitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-03","primaryCompletion":"2007-06","completion":"2007-06","firstPosted":"2007-03-28","resultsPosted":"2010-05-17","lastUpdate":"2022-02-09"},"enrollment":426,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Seasonal Allergic Rhinitis"],"interventions":[{"type":"DRUG","name":"mometasone furoate","otherNames":["Nasonex","SCH 32088"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"MFNS 200 mcg QD","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study is designed to assess the effectiveness of mometasone furoate nasal spay (MFNS) once daily (QD) compared with placebo in subjects with seasonal allergic rhinitis (SAR) in reducing the total nasal symptom score and the total ocular symptom score.","primaryOutcome":{"measure":"Change From Baseline in the Average AM Instantaneous (NOW) Total Nasal Symptom Score (TNSS) Averaged Over Days 2 to 15","timeFrame":"Baseline and 15 days","effectByArm":[{"arm":"Mometasone Furoate Nasal Spray (MFNS)","deltaMin":9.83,"sd":1.56},{"arm":"Placebo","deltaMin":9.69,"sd":1.56}],"pValues":[{"comp":"OG000 vs OG001","p":"0.001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":8},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["21261661"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":211},"commonTop":[]}}